Ian Krop

Ian Krop led the KATHERINE trial that established T-DM1 as the standard of care for HER2-positive patients with residual disease after neoadjuvant therapy, a practice-changing result for post-neoadjuvant breast cancer management. His research encompasses antibody-drug conjugate development across breast cancer subtypes and investigation of resistance mechanisms to HER2-targeted therapies. He contributes to ASCO guidelines for HER2-positive breast cancer and has been a key figure in translating novel HER2-directed agents from bench to clinic. Krop continues to investigate optimal post-neoadjuvant and adjuvant strategies for HER2+ early breast cancer.